Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "IDH1" Clear all
Completed Phase 2 Interventional Results available

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

NCT03207347
View directory record Official record
Conditions
Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
Niraparib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting Phase 1 Interventional

Chronic CED of TPT for Recurrent Malignant Glioma

NCT06666712
View directory record Official record
Conditions
Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation
Interventions
Topotecan
Drug
Lead sponsor
Jeffrey N. Bruce
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Not listed No phase listed Observational

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

NCT00900224
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, DNA methylation analysis, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting Phase 4 Interventional

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

NCT07486713
View directory record Official record
Conditions
AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
Interventions
Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

NCT05921760
View directory record Official record
Conditions
IDH1-mutant Cholangiocarcinoma
Interventions
Ivosidenib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting Phase 1 Interventional

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

NCT05756777
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Gilteritinib, Ivosidenib, Enasidenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

NCT01802333
View directory record Official record
Conditions
Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride, Idarubicin, Laboratory Biomarker Analysis, Vorinostat
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
441
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 302 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting Phase 1 Interventional

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

NCT06543381
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Olutasidenib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Duarte, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting Phase 3 Interventional

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

NCT07215910
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 3
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
Radiation · Procedure · Drug + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
12 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
82
States / cities
Duarte, California • Irvine, California • Orange, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

NCT02677922
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AG-120, Azacitidine, AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
9
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting Phase 3 Interventional

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953
View directory record Official record
Conditions
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Interventions
Ivosidenib, Azacitidine
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting Phase 1 Interventional

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

NCT05609994
View directory record Official record
Conditions
Low Grade Glioma of Brain
Interventions
PEPIDH1M vaccine + vorasidenib
Drug
Lead sponsor
Katy Peters, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 23, 2026, 10:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555
View directory record Official record
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Suspended Phase 2 Interventional

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

NCT03952598
View directory record Official record
Conditions
Glioma, Gliomas, High Grade Glioma, Malignant Glioma, Low Grade Glioma
Interventions
HP 13C Pyruvate, 3T MRI scanner
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

NCT02684838
View directory record Official record
Conditions
CNS Tumor
Interventions
Not listed
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
31
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

NCT02989857
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions
AG-120, Placebo
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jul 23, 2026, 10:46 PM EDT
Terminated Phase 2Phase 3 Interventional

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

NCT02414165
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Jul 23, 2026, 10:46 PM EDT
Withdrawn Not applicable Interventional

Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

NCT06648473
View directory record Official record
Conditions
Low Grade Glioma of Brain
Interventions
MRI Scan
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors

NCT02746081
View directory record Official record
Conditions
Solid Tumors
Interventions
BAY1436032
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 23, 2026, 10:46 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions
Iomab-B, Conventional Care, HCT
Drug · Procedure
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

NCT03564821
View directory record Official record
Conditions
IDH1 Mutation Myeloid Neoplasms
Interventions
Ivosidenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

NCT03127735
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
BAY1436032
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Buffalo, New York • New York, New York • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Jul 23, 2026, 10:46 PM EDT
Withdrawn Phase 1 Interventional

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

NCT04655391
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia
Interventions
Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate, Gilteritinib Fumarate, Glasdegib Maleate, Ivosidenib, Venetoclax
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Jul 23, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

NCT03303950
View directory record Official record
Conditions
Anemia, ASXL1 Gene Mutation, EZH2 Gene Mutation, IDH1 Gene Mutation, IDH2 Gene Mutation, Plasma Cell Myeloma, Primary Myelofibrosis, Recurrent Plasma Cell Myeloma, Secondary Myelofibrosis, Thrombocytopenia
Interventions
Busulfan, Cyclophosphamide, Fludarabine, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 23, 2026, 10:46 PM EDT